Skip to main content Skip to section navigation Skip to footer
Inhibikase Therapeutics, Inc.
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Science Advisors
  • Technology
    • Overview
    • RAMP™ Drug Innovation Engine
  • Pipeline
    • Overview
    • IkT-148009 for Parkinson’s Disease and GI complications
    • IkT-001Pro for CML
    • IkT-01427 for PML
    • Collaborative Programs
    • Partnering with Inhibikase
  • Scientific Publications
  • Clinical Trials
  • News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact
  • Careers

Press Releases

News

News

  • Press Releases
Apr 21, 2021 8:00am EDT

Inhibikase Therapeutics to Present at Sachs 4th Annual Neuroscience Innovation Forum

Apr 01, 2021 8:00am EDT

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity

Mar 02, 2021 8:05am EST

Inhibikase Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Virtual Conference

Feb 22, 2021 8:05am EST

Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference

Feb 17, 2021 8:05am EST

Inhibikase Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial of IkT-148009 to Treat Parkinson’s Disease and Related Disorders

Jan 04, 2021 8:01am EST

Inhibikase Therapeutics Announces Partnership with Clintrex Research Corporation; C. Warren Olanow, MD, to Serve as Interim Chief Medical Officer

Dec 28, 2020 10:33am EST

Inhibikase Therapeutics Announces Closing of Initial Public Offering

Dec 22, 2020 6:25pm EST

Inhibikase Therapeutics, Inc. Announces Pricing of its Initial Public Offering

Dec 03, 2020 8:30am EST

Inhibikase Advances Development Program for Multiple System Atrophy (MSA) Based on Demonstration of Key Role of c-Abl Kinase in MSA Neurodegeneration

Jul 27, 2020 11:28am EDT

Inhibikase Files Registration Statement for Proposed Initial Public Offering

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook
  • Visit us on Twitter
  • Visit us on Linkedin
  • Visit us on Youtube
©2023 Inhibikase Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap